BioCorteX Announces Strategic Partnership with CD Biopharma to Accelerate Global Precision Oncology

Author: BioCorteX Team

Theme: Strategic Partnerships, Cross-Border Drug Development

Key Words: Precision Medicine, Immunotherapy, Anti-PD-1, Microbiome, Carbon Mirror, China-Global

BioCorteX is delighted to announce a strategic collaboration with CD Biopharma (https://www.cdbiopharma.com/en_index.html), a leading Chinese biotechnology company. This partnership represents an important milestone in our mission to accelerate the development of next-generation precision immunotherapies for solid tumours.

By combining our Carbon Mirror™ (https://biocortex.com/platform/) technology with CD Biopharma’s innovative Bispecific Fusion Protein (BsFP) platform, we aim to de-risk drug development, optimise global trial strategy, and chart the optimal route for bringing life-changing treatments to patients worldwide.

The Context: Bridging the Regional Gap

As discussed in our recent article The Challenges of Moving Oncology Assets Between Regions (https://biocortex.com/challenges-of-moving-oncology-assets-between-regions/), moving pharmaceutical assets from China to global markets presents unique hurdles.

While the innovation occurring within the Chinese biotech space is immense, assets often face “translation” issues when trialled in new geographies. Beyond germline genetics and ethnicity, one underappreciated dimension is variation in intra-tumour bacterial composition. Tumours across populations harbour distinct bacterial communities that influence immune tone, tumour metabolism, and response to immunotherapies, including PD-1 blockade. If these differences aren’t accounted for, a drug that works brilliantly in a Shanghai trial might see variable results in New York, risking the asset’s entire future.

The Collaboration

CD Biopharma has rapidly emerged as an innovative force in precision immunotherapy. Their proprietary platform targets specific cells to precisely tune immune responses.

Their leading clinical candidate, CD-001, is a perfect example of next-generation ingenuity. It is a bispecific fusion protein that combines anti-PD-1 blockade with a targeted IL-21 mutant. This dual mechanism aims to reinvigorate exhausted T-cells and precisely deliver cytokines to the tumour microenvironment. CD-001 has already achieved Investigational New Drug (IND) approvals from both the U.S. FDA and China’s NMPA.

Through this alliance, BioCorteX will utilise our Carbon Mirror™ platform to test candidates like CD-001 in silico. By emulating clinical trials before they happen, we can assess potential efficacy across different tumour types, regions, and patient communities.

Why does it matter? The PD-1 Connection

A growing body of evidence shows that the efficacy of anti-PD-1 therapies is strongly shaped by drug–bacteria interactions within the tumour.

Because CD-001 acts through the PD-1 axis, understanding how intra-tumour bacterial profiles vary across regions is crucial for ensuring consistent global performance. BioCorteX provides the “unified biology” context to predict these interactions. We can simulate how CD-001 will behave in the region-specific bacterial ecologies of US or European patients before a single patient is enrolled.

“Our technology offers CD Biopharma and others a capability no other company can. Our Carbon Mirror™ technology allows us to test drugs in silico and chart the optimal route to success… helping the company increase the probability of success of CD-001 across geographies. That knowledge de-risks development, unlocking value.” — Nik Sharma, Co-Founder and CEO of BioCorteX

Our Value Proposition

This partnership exemplifies how BioCorteX transforms complex biological data into executable insights. By understanding the deep interactions between drugs and the patient’s unique biology (including drug-bacteria interactions), we can help partners like CD Biopharma mitigate the risks of “moving regions.”

Dr. Alan Xu, CEO of CD Biopharma, highlighted the impact of this synergy:

“Their expertise in in silico drug development, combined with our cutting-edge precision immunotherapy platform, creates a powerful synergy that will accelerate our path to bringing life-changing treatments to patients worldwide.”

Contact us for more information on how we can help de-risk your asset!

DISCLAIMER: The information provided by BioCorteX Inc. is for general informational purposes only and should not be construed as medical advice. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Any mention of specific treatments is for informational purposes only and does not constitute an endorsement or recommendation by BioCorteX. BioCorteX is not responsible for any errors or omissions or for any actions taken based on the information provided.